

Amendments to the Claims

Please amend claims 15, 22 and 37 as indicated in the listing of claims.

The listing of claims will replace all prior versions, and listings of claims in the application.

Listing of Claims:

1.-14. (Canceled).

15. (Currently amended) An isolated antibody that specifically binds to a C-terminal fragment of connective tissue growth factor (CTGF) polypeptide, but not platelet derived growth factor (PDGF), wherein the antibody inhibits DNA synthesis, and wherein the C-terminal fragment of CTGF ~~consists of an~~ is amino acid residues ~~sequence selected from the group consisting of:~~

- (a) ~~residue~~ 4 through 74 of SEQ ID NO:4; or
- (b) ~~residue~~ 75 through 172 of SEQ ID NO:4; or
- (c) ~~residue~~ 4 through 172 of SEQ ID NO:4.

16.-18. (Canceled).

19. (Original) The antibody of claim 15, wherein the antibody is a monoclonal antibody.

20. (Original) The antibody of claim 19, wherein the antibody is a human monoclonal antibody.

21. (Original) The antibody of claim 15, wherein the antibody is a polyclonal antibody.

22. (Currently amended) The antibody of claim 15, wherein the antibody ~~comprises murine antigen-binding-region residues~~ is a murine antibody.

23. (Original) A composition comprising the antibody of claim 15 and a pharmaceutically acceptable excipient or carrier.

24.-36. (Canceled).

37. (Currently amended) The antibody of claim ~~48~~ 15, wherein the antibody is a humanized ~~comprises human antibody residues~~.